<?xml version='1.0' encoding='utf-8'?>
<document id="26097794"><sentence text="Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Pharmacokinetic Parameters of Rosiglitazone in Healthy Subjects."><entity charOffset="21-26" id="DDI-PubMed.26097794.s1.e0" text="Ethyl" /><entity charOffset="28-61" id="DDI-PubMed.26097794.s1.e1" text="Eicosapentaenoic Acid Ethyl Ester" /><entity charOffset="96-109" id="DDI-PubMed.26097794.s1.e2" text="Rosiglitazone" /><entity charOffset="50-62" id="DDI-PubMed.26097794.s1.e3" text="Ethyl" /><pair ddi="false" e1="DDI-PubMed.26097794.s1.e0" e2="DDI-PubMed.26097794.s1.e0" /><pair ddi="false" e1="DDI-PubMed.26097794.s1.e0" e2="DDI-PubMed.26097794.s1.e1" /><pair ddi="false" e1="DDI-PubMed.26097794.s1.e0" e2="DDI-PubMed.26097794.s1.e3" /><pair ddi="false" e1="DDI-PubMed.26097794.s1.e0" e2="DDI-PubMed.26097794.s1.e2" /><pair ddi="false" e1="DDI-PubMed.26097794.s1.e1" e2="DDI-PubMed.26097794.s1.e1" /><pair ddi="false" e1="DDI-PubMed.26097794.s1.e1" e2="DDI-PubMed.26097794.s1.e3" /><pair ddi="false" e1="DDI-PubMed.26097794.s1.e1" e2="DDI-PubMed.26097794.s1.e2" /><pair ddi="false" e1="DDI-PubMed.26097794.s1.e3" e2="DDI-PubMed.26097794.s1.e3" /><pair ddi="false" e1="DDI-PubMed.26097794.s1.e3" e2="DDI-PubMed.26097794.s1.e2" /></sentence><sentence text="Icosapent ethyl is a high-purity form of eicosapentaenoic acid ethyl ester approved to reduce triglyceride levels in adults with triglycerides ≥500 mg/dL"><entity charOffset="10-15" id="DDI-PubMed.26097794.s2.e0" text="ethyl" /><entity charOffset="41-74" id="DDI-PubMed.26097794.s2.e1" text="eicosapentaenoic acid ethyl ester" /><entity charOffset="94-106" id="DDI-PubMed.26097794.s2.e2" text="triglyceride" /><entity charOffset="129-142" id="DDI-PubMed.26097794.s2.e3" text="triglycerides" /><entity charOffset="63-75" id="DDI-PubMed.26097794.s2.e4" text="ethyl" /><pair ddi="false" e1="DDI-PubMed.26097794.s2.e0" e2="DDI-PubMed.26097794.s2.e0" /><pair ddi="false" e1="DDI-PubMed.26097794.s2.e0" e2="DDI-PubMed.26097794.s2.e1" /><pair ddi="false" e1="DDI-PubMed.26097794.s2.e0" e2="DDI-PubMed.26097794.s2.e4" /><pair ddi="false" e1="DDI-PubMed.26097794.s2.e0" e2="DDI-PubMed.26097794.s2.e2" /><pair ddi="false" e1="DDI-PubMed.26097794.s2.e0" e2="DDI-PubMed.26097794.s2.e3" /><pair ddi="false" e1="DDI-PubMed.26097794.s2.e1" e2="DDI-PubMed.26097794.s2.e1" /><pair ddi="false" e1="DDI-PubMed.26097794.s2.e1" e2="DDI-PubMed.26097794.s2.e4" /><pair ddi="false" e1="DDI-PubMed.26097794.s2.e1" e2="DDI-PubMed.26097794.s2.e2" /><pair ddi="false" e1="DDI-PubMed.26097794.s2.e1" e2="DDI-PubMed.26097794.s2.e3" /><pair ddi="false" e1="DDI-PubMed.26097794.s2.e4" e2="DDI-PubMed.26097794.s2.e4" /><pair ddi="false" e1="DDI-PubMed.26097794.s2.e4" e2="DDI-PubMed.26097794.s2.e2" /><pair ddi="false" e1="DDI-PubMed.26097794.s2.e4" e2="DDI-PubMed.26097794.s2.e3" /><pair ddi="false" e1="DDI-PubMed.26097794.s2.e2" e2="DDI-PubMed.26097794.s2.e2" /><pair ddi="false" e1="DDI-PubMed.26097794.s2.e2" e2="DDI-PubMed.26097794.s2.e3" /></sentence><sentence text=" Candidates for triglyceride-lowering therapy include patients with diabetes mellitus who may be receiving rosiglitazone"><entity charOffset="16-28" id="DDI-PubMed.26097794.s3.e0" text="triglyceride" /><entity charOffset="107-120" id="DDI-PubMed.26097794.s3.e1" text="rosiglitazone" /><pair ddi="false" e1="DDI-PubMed.26097794.s3.e0" e2="DDI-PubMed.26097794.s3.e0" /><pair ddi="false" e1="DDI-PubMed.26097794.s3.e0" e2="DDI-PubMed.26097794.s3.e1" /></sentence><sentence text=" We assessed the effects of icosapent ethyl on the pharmacokinetic parameters of rosiglitazone"><entity charOffset="38-43" id="DDI-PubMed.26097794.s4.e0" text="ethyl" /><entity charOffset="81-94" id="DDI-PubMed.26097794.s4.e1" text="rosiglitazone" /><pair ddi="false" e1="DDI-PubMed.26097794.s4.e0" e2="DDI-PubMed.26097794.s4.e0" /><pair ddi="false" e1="DDI-PubMed.26097794.s4.e0" e2="DDI-PubMed.26097794.s4.e1" /></sentence><sentence text="" /><sentence text="Subjects received a single 8-mg oral dose of rosiglitazone alone and with oral icosapent ethyl 4 g/day in this open-label drug-drug interaction study"><entity charOffset="45-58" id="DDI-PubMed.26097794.s6.e0" text="rosiglitazone" /><entity charOffset="89-94" id="DDI-PubMed.26097794.s6.e1" text="ethyl" /><pair ddi="false" e1="DDI-PubMed.26097794.s6.e0" e2="DDI-PubMed.26097794.s6.e0" /><pair ddi="false" e1="DDI-PubMed.26097794.s6.e0" e2="DDI-PubMed.26097794.s6.e1" /></sentence><sentence text=" Pharmacokinetic end points included area under the concentration versus time curve from time zero to infinity (AUC0-inf) and maximum observed concentration (Cmax) for rosiglitazone with and without icosapent ethyl"><entity charOffset="168-181" id="DDI-PubMed.26097794.s7.e0" text="rosiglitazone" /><entity charOffset="209-214" id="DDI-PubMed.26097794.s7.e1" text="ethyl" /><pair ddi="false" e1="DDI-PubMed.26097794.s7.e0" e2="DDI-PubMed.26097794.s7.e0" /><pair ddi="false" e1="DDI-PubMed.26097794.s7.e0" e2="DDI-PubMed.26097794.s7.e1" /></sentence><sentence text="" /><sentence text="Of 30 subjects enrolled, 28 completed the study" /><sentence text=" Icosapent ethyl 4 g/day at steady-state did not significantly change the single-dose AUC0-inf or Cmax of rosiglitazone 8 mg"><entity charOffset="106-119" id="DDI-PubMed.26097794.s10.e0" text="rosiglitazone" /><entity charOffset="11-23" id="DDI-PubMed.26097794.s10.e1" text="ethyl" /><pair ddi="false" e1="DDI-PubMed.26097794.s10.e1" e2="DDI-PubMed.26097794.s10.e1" /><pair ddi="false" e1="DDI-PubMed.26097794.s10.e1" e2="DDI-PubMed.26097794.s10.e0" /></sentence><sentence text=" Least squares geometric mean ratios (90% confidence interval) for AUC0-inf and Cmax of rosiglitazone given with icosapent ethyl versus rosiglitazone alone were 0"><entity charOffset="88-101" id="DDI-PubMed.26097794.s11.e0" text="rosiglitazone" /><entity charOffset="123-128" id="DDI-PubMed.26097794.s11.e1" text="ethyl" /><entity charOffset="136-149" id="DDI-PubMed.26097794.s11.e2" text="rosiglitazone" /><pair ddi="false" e1="DDI-PubMed.26097794.s11.e0" e2="DDI-PubMed.26097794.s11.e0" /><pair ddi="false" e1="DDI-PubMed.26097794.s11.e0" e2="DDI-PubMed.26097794.s11.e1" /><pair ddi="false" e1="DDI-PubMed.26097794.s11.e0" e2="DDI-PubMed.26097794.s11.e2" /><pair ddi="false" e1="DDI-PubMed.26097794.s11.e1" e2="DDI-PubMed.26097794.s11.e1" /><pair ddi="false" e1="DDI-PubMed.26097794.s11.e1" e2="DDI-PubMed.26097794.s11.e2" /></sentence><sentence text="90 (87" /><sentence text="00-93" /><sentence text="40) and 1" /><sentence text="01 (92" /><sentence text="02-109" /><sentence text="9), respectively" /><sentence text=" No serious adverse events were reported and no subject discontinued due to an adverse event" /><sentence text="" /><sentence text="At steady-state concentrations, icosapent ethyl did not inhibit the pharmacokinetics of rosiglitazone"><entity charOffset="42-47" id="DDI-PubMed.26097794.s20.e0" text="ethyl" /><entity charOffset="88-101" id="DDI-PubMed.26097794.s20.e1" text="rosiglitazone" /><pair ddi="false" e1="DDI-PubMed.26097794.s20.e0" e2="DDI-PubMed.26097794.s20.e0" /><pair ddi="false" e1="DDI-PubMed.26097794.s20.e0" e2="DDI-PubMed.26097794.s20.e1" /></sentence><sentence text=" Co-administration of icosapent ethyl and rosiglitazone was safe and well tolerated"><entity charOffset="32-37" id="DDI-PubMed.26097794.s21.e0" text="ethyl" /><entity charOffset="42-55" id="DDI-PubMed.26097794.s21.e1" text="rosiglitazone" /><pair ddi="false" e1="DDI-PubMed.26097794.s21.e0" e2="DDI-PubMed.26097794.s21.e0" /><pair ddi="false" e1="DDI-PubMed.26097794.s21.e0" e2="DDI-PubMed.26097794.s21.e1" /></sentence><sentence text="" /></document>